文献速递鼻科

植物药ELOM-080治疗急性病毒性鼻窦炎:一项随机、安慰剂对照、盲法临床试验

Phytomedicine ELOM-080 in Acute Viral Rhinosinusitis: A Randomized, Placebo-Controlled, Blinded Clinical Trial.
PubMed 文献 · Laryngoscope · 2022-10-12

这项前瞻性随机安慰剂对照双盲试验纳入463例急性病毒性鼻窦炎患者,口服ELOM-080(每日4次、每次1粒)或匹配安慰剂。结果显示ELOM-080在第4天显著改善主观疾病负担(MSS,p=0.012),研究者评估的MSS在第3次和第4次访视均显著优于安慰剂(p=0.016、p=0.014),症状缓解提前3天,两种治疗均耐受良好。

要点

  • ELOM-080每日4次、每次1粒口服,第4天主观MSS较安慰剂显著改善(p=0.012)。
  • 研究者评估MSS在第3次访视(p=0.016)和第4次访视(p=0.014)均显著优于安慰剂。
  • 症状缓解提前3天,SNOT-20 GAV改善更明显,两种治疗均耐受良好。

核心结论

  • ELOM-080较安慰剂显著改善急性病毒性鼻窦炎的疾病负担,症状缓解提前3天,结果证实其疗效与安全性。

研究设计与样本

  • 前瞻性、随机、安慰剂对照、双盲临床试验,共随机463例急性病毒性鼻窦炎患者,口服ELOM-080或匹配安慰剂(每日4次、每次1粒)。

主要发现

  • 第4天主观疾病负担(MSS)较安慰剂显著改善(p=0.012)。
  • 第一周MSS评分改善约提前1天,第二周改善约提前3天。
  • 研究者评估的平均MSS在第3次访视(p=0.016)和第4次访视(p=0.014)均显著优于安慰剂。
  • 气味识别评分在两种治疗中改善程度相当,SNOT-20 GAV改善在ELOM-080组更明显。
  • ELOM-080治疗显示降低病毒载量的潜力,两种治疗均耐受良好。

关键数值与推荐

  • 主要终点为治疗7天和14天后研究者评估的主要症状评分(MSSINV)变化。
  • 次要终点包括患者评估的MSS(MSSPAT)、嗅觉功能(12项Sniffin' Sticks)、SNOT-20 GAV、病毒载量影响及安全性。
  • 证据等级为1级。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: ELOM-080 is a phytomedicine approved for the treatment of acute and chronic inflammatory diseases of the respiratory tract, sinusitis, and bronchitis in particular. This prospective, randomized, placebo-controlled, double-blind clinical trial was conducted to assess efficacy and safety of ELOM-080 in the treatment of acute viral rhinosinusitis (AVRS). METHODS: Patients with AVRS received oral treatment (4 × 1 capsule per day) with either ELOM-080 or matching placebo. Primary endpoints were the change in major symptom score (MSS) after 7 and 14 days of treatment assessed by the investigator (MSSINV ). Secondary endpoints were changes in MSS assessed by the patients (MSSPAT ), olfactory function (12-item Sniffin' Sticks), 20-Item Sino-Nasal Outcome Test (SNOT-20 GAV; German adapted version), influence of treatment on viral load, and safety. RESULTS: Four hundred and sixty-three patients were randomized. At day 4, subjective burden of disease (MSS) was significantly ameliorated compared to placebo (p = 0.012). During the first treatment week MSS scores improved about 1 day earlier, and 3 days earlier in the second week. Effect with ELOM-080 on mean MSSINV was statistically significantly superior to placebo at visit 3 (p = 0.016) and visit 4 (p = 0.014). In chemosensory testing identification scores improved comparably in both treatments. The improvement of the SNOT-20 GAV was more pronounced in ELOM-080 patients. Treatment with ELOM-080 indicated a potential for decreasing viral load. Both treatments were well tolerated. CONCLUSION: ELOM-080 improves the burden of AVRS significantly in comparison to placebo, remission of symptoms occurred 3 days earlier. The results confirm the efficacy and safety of ELOM-080 for treatment of AVRS. LEVEL OF EVIDENCE: 1 Laryngoscope, 133:1576-1583, 2023.

来源:Laryngoscope,查看原文。版权归原作者所有。

引用

  1. Pfaar O, Beule AG, Jobst D, et al. Phytomedicine ELOM-080 in Acute Viral Rhinosinusitis: A Randomized, Placebo-Controlled, Blinded Clinical Trial. Laryngoscope. 2022. PMID: 36222438. doi:10.1002/lary.30418

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。